Necrosis News and Research

RSS

Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI

A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain injury can rapidly improve following a single dose of a drug that targets brain inflammation, even years after the stroke or traumatic event.

1 Nov 2012

$Ustekinumab success in refractory Crohn’s disease$

Ustekinumab success in refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti–tumor necrosis factor treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

22 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Cytokine levels altered in FEP, schizophrenia patients

Levels of certain cytokines are altered in patients with first-episode psychosis and patients with schizophrenia, research shows.

17 Oct 2012

Experts blaze TRAIL for pulmonary arterial hypertension therapy

Researchers have shown that the cell signaling molecule tumor necrosis factor-related apoptosis-inducing ligand may be a potential therapeutic target for pulmonary arterial hypertension.

16 Oct 2012

Sterile acellular matrices 'reliable in expander-based breast reconstruction'

Sterile human acellular dermal matrix offers reliable matrix incorporation and a low complication rate for expander-based breast reconstruction, the results of a US study indicate, which also suggest that sterilization does not affect incorporation success.

15 Oct 2012

Rheumatoid arthritis treatment foiled by gum disease

Periodontal disease may reduce the efficacy of tumor necrosis factor inhibitor treatment in patients with rheumatoid arthritis, preliminary research suggests.

15 Oct 2012

Pioneering research paves way for new treatments for pulmonary arterial hypertension

Pioneering research conducted by the University of Sheffield is paving the way for new treatments which could benefit patients suffering from the fatal lung disease pulmonary arterial hypertension (PAH).

15 Oct 2012

New insights into how miR-30d can promote healthy insulin production

Work by Michigan Technological University biologist Xiaoqing Tang is yielding new insights into how a tiny snippet of genetic material can promote healthy insulin production in mice.

13 Oct 2012

Blood clot-busting enzymes much busier than previously imagined

The body's blood clot-busting enzymes are much busier than previously imagined, with new research showing that they also dispose of every cell that dies prematurely from disease or trauma.

5 Oct 2012

New treatment target brings hope for scleroderma patients

Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the SMAD protein may be a viable therapeutic target in scleroderma patients.

1 Oct 2012

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

Low-cost thermometer identifies cows with poor hoof health

A low-cost hand-held infrared thermometer can successfully identify cows with potentially treatable hoof lesions, report researchers in the Veterinary Record.

26 Sep 2012

Study reveals potential of NIR spectral imaging for intra-operative skin flap assessment

In 2010 breast reconstruction entered the Top Five list of reconstructive procedures in the US, with 93,000 procedures performed, up 8% from 2009, and 18% from 2000. This is among the most common skin flap procedure performed.

24 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Plastic hearts still break

Renewal of cells in the human heart occurs throughout life and is boosted by, but cannot prevent, the effects of aging and cardiomyopathy, a study shows.

18 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012